Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. by El-Jawhari, J, El-Sherbiny, Y, Scott, G, Morgan, R, Prestwich, R, Bowles, P, Blair, G, Tanaka, T, Rabbitts, T, Meade, J, Cook, G

Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. by West, E, Morgan, R, Scott, K, Merrick, A, Lubenko, A, Pawson, D, Selby, P, Hatfield, P, Prestwich, R, Fraser, S, Eves, D, Anthoney, A, Twelves, C, Beirne, D, Patel, P, O'Donnell, D, Watt, S, Waller, M, Dietz, A, Robinson, P, Melcher, A